Healthcare
Spectral Medical Inc.(EDTXF)
Live Price
Offline$0.986
+0.20% today
1Y Change
+67.12%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $410.00M
- Revenue Growth
- +6.7%
- EPS Growth
- -190.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Spectral Medical Inc. (EDTXF) is a Healthcare stock with a market cap of $410.00M and listed on OTC. The stock last traded around $0.99 and up 67.1% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +6.7%, EPS growth of -190.9%, a dividend yield of 0.0%. What stands out right now is revenue +6.7%, EPS -190.9%, free cash flow -9.9% with operating margin -472.6% and ROIC 26.5%. Valuation already assumes a fairly strong business story at price/sales 167.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EDTXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.7% vs +7.6% peer median
Operating Margin
Below sector median
-472.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.7% and EPS is at -190.9%, with operating margin around -472.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -0.8% | -0.8% | -0.8% |
2026 Mar 26, 2026 | -37.4% | -4.6% | -7.4% | -5.6% |
2025 Nov 7, 2025 | -1014.2% | +6.1% | +0.2% | -5.0% |
Benchmark Edge
EDTXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EDTXF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EDTXF Max Drawdown
-33.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EDTXF and SPY.
Company Overview
Spectral Medical Inc.
Other OTC
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
- Leadership
- Christopher Seto
- IPO Date
- Dec 18, 2009
- Employees
- 29
- Street Address
- 135 The West Mall
- Mailing
- Toronto, ON, M9C 1C2
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 416-626-3233
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 167.0
- Price/Book
- โ
Growth
- Revenue
- +6.7%
- EPS
- -190.9%
- Free Cash Flow
- -9.9%
Profitability
- Gross Margin
- 12.3%
- Operating Margin
- -472.6%
- Net Margin
- -1952.9%
- ROE
- 87.8%
- ROIC
- 26.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.